As of June 30, 2026, Adagene Inc. reported preliminary, unaudited cash and cash equivalents totaling US$127.9 million. This figure is subject to finalization and should not replace audited financial statements prepared under US GAAP. Adagene Inc. is a biotechnology company focused on drug discovery and development.